Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Short

Showing results (111-120 of 346) with videos related to

Pageof 35
Sort By:
Journal of Hematology & Oncology|May 14, 2025
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomabNicholas J Short, Hagop Kantarjian, Ken Furudate, et al.
American Journal of Hematology|June 23, 2021
Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER studyElias Jabbour, Keyur Patel, Nitin Jain, et al.
Cancer|February 21, 2025
Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaEitan Kugler, Hagop Kantarjian, Elias Jabbour, et al.
Acta Haematologica|November 25, 2020
Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of TransplantBachar Samra, Hagop M Kantarjian, Koji Sasaki, et al.
Haematologica|December 10, 2020
Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemiaIman Abou Dalle, Ronald Paranal, Jabra Zarka, et al.
Blood Cancer Journal|October 21, 2025
Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALLNicholas J Short, Elias Jabbour, Walid Macaron, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 21, 2017
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive LeukemiaRita Assi, Hagop Kantarjian, Nicholas J Short, et al.
American Journal of Hematology|April 12, 2024
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapyNicholas J Short, Elias Jabbour, Lewis F Nasr, et al.
American Journal of Hematology|January 6, 2025
Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic LeukemiaHagop Kantarjian, Nicholas J Short, Nitin Jain, et al.
Cancer|April 9, 2026
Outcome of second-line therapy in adult B-cell acute lymphoblastic leukemiaHagop Kantarjian, Wei Qiao, Nitin Jain, et al.
Pageof 35

Showing results (111-120 of 346) with videos related to

Sort By:
Pageof 35
Journal of Hematology & Oncology|May 14, 2025
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomabNicholas J Short, Hagop Kantarjian, Ken Furudate, et al.
American Journal of Hematology|June 23, 2021
Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER studyElias Jabbour, Keyur Patel, Nitin Jain, et al.
Cancer|February 21, 2025
Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaEitan Kugler, Hagop Kantarjian, Elias Jabbour, et al.
Acta Haematologica|November 25, 2020
Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of TransplantBachar Samra, Hagop M Kantarjian, Koji Sasaki, et al.
Haematologica|December 10, 2020
Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemiaIman Abou Dalle, Ronald Paranal, Jabra Zarka, et al.
Blood Cancer Journal|October 21, 2025
Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALLNicholas J Short, Elias Jabbour, Walid Macaron, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 21, 2017
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive LeukemiaRita Assi, Hagop Kantarjian, Nicholas J Short, et al.
American Journal of Hematology|April 12, 2024
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapyNicholas J Short, Elias Jabbour, Lewis F Nasr, et al.
American Journal of Hematology|January 6, 2025
Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic LeukemiaHagop Kantarjian, Nicholas J Short, Nitin Jain, et al.
Cancer|April 9, 2026
Outcome of second-line therapy in adult B-cell acute lymphoblastic leukemiaHagop Kantarjian, Wei Qiao, Nitin Jain, et al.
Pageof 35